Goodwill £m	Software £m	Development costs £m	Patent rights £m	Marketing authorisations £m	Acquired intangibles £m	Total £m
Cost
At 1 July 2017	128.1	12.7	11.7	5.3	1.0	409.4	568.2
Additions	–	4.2	1.7	0.9	–	8.7	15.5
Acquisitions through business combinations	102.3	–	–	(2.1)	–	262.3	362.5
Remeasurement	–	–	–	–	–	(3.1)	(3.1)
Disposals	–	–	(0.2)	(0.2)	–	–	(0.4)
Foreign exchange adjustments	(1.1)	(0.2)	–	–	(0.1)	(3.3)	(4.7)
At 30 June 2018 and 1 July 2018	229.3	16.7	13.2	3.9	0.9	674.0	938.0
Additions	–	2.8	1.2	–	–	7.9	11.9
Acquisitions through business combinations	18.8	0.1	–	0.4	–	18.2	37.5
Remeasurement	–	–	–	–	–	(1.5)	(1.5)
Disposals	–	–	(0.3)	–	–	–	(0.3)
Foreign exchange adjustments	4.0	0.1	(0.1)	–	–	11.2	15.2
At 30 June 2019	252.1	19.7	14.0	4.3	0.9	709.8	1,000.8
Accumulated Amortisation
At 1 July 2017	–	2.9	6.1	3.1	–	159.8	171.9
Charge for the year	–	0.8	1.2	0.5	–	54.1	56.6
Acquisitions through business combinations	–	–	–	(0.4)	–	–	(0.4)
Impairment	–	0.1	–	–	–	–	0.1
Disposals	–	–	(0.2)	(0.2)	–	–	(0.4)
Foreign exchange adjustments	–	(0.1)	–	–	–	0.5	0.4
At 30 June 2018 and 1 July 2018	–	3.7	7.1	3.0	–	214.4	228.2
Charge for the year	–	2.5	1.3	0.3	–	76.8	80.9
Foreign exchange adjustments	–	(0.1)	0.1	–	–	4.7	4.7
At 30 June 2019	–	6.1	8.5	3.3	–	295.9	313.8
Net book value
At 30 June 2019	252.1	13.6	5.5	1.0	0.9	413.9	687.0
At 30 June 2018	229.3	13.0	6.1	0.9	0.9	459.6	709.8

The assets within patent rights comprises the rights to Equidone® (which was launched in the USA during 2011, and has a carrying value of £0.3 million with a remaining amortisation period of 2 years), and the in-licensed products within Canada (acquired in 2016 with a carrying value of £0.3 million and has a remaining amortisation period of 7.5 years). During the year, £0.4 million was added to patent rights within EU Pharmaceuticals Segment from the acquisition of Venco.

£0.8 million of the marketing authorisations relate to the Vetivex® range of products. Ownership of the marketing authorisations rests with the Group in perpetuity. There are not believed to be any legal, regulatory or contractual provisions that limit their useful lives. Vetivex is an established range of products which are relatively simple in nature and there are a limited number of players in the market. Accordingly, the Directors believe that it is appropriate that the marketing authorisations are treated as having indefinite lives for accounting purposes.

Goodwill is allocated across cash generating units that are expected to benefit from that business combination. Key assumptions made in this respect are given in note 14.

During the year, the contingent consideration in relation to development milestones and sales milestones of the acquired intangibles has been remeasured and to the extent possible remeasured against the intangibles.

In accordance with the disclosure requirements of IAS 38 'Intangible Assets', the components of acquired intangibles are summarised below:

	Commercial relationships £m	Pharmacological process £m	Brand £m	Capitalised development costs £m	Product rights £m	Total £m
Cost
At 1 July 2017	1.7	50.5	13.3	114.5	229.4	409.4
Additions	–	–	–	–	8.7	8.7
Acquisitions through business combinations	4.9	–	2.4	255.0	–	262.3
Remeasurement	–	–	–	–	(3.1)	(3.1)
Foreign exchange adjustments	0.1	(0.9)	(0.3)	(2.2)	–	(3.3)
At 30 June 2018 and 1 July 2018	6.7	49.6	15.4	367.3	235.0	674.0
Additions	–	–	–	–	7.9	7.9
Reclassification*	–	–	–	2.9	(2.9)	–
Acquisitions through business combinations	–	–	0.6	17.6	–	18.2
Remeasurement	–	–	–	–	(1.5)	(1.5)
Foreign exchange adjustments	0.1	1.8	0.3	5.8	3.2	11.2
At 30 June 2019	6.8	51.4	16.3	393.6	241.7	709.8
Accumulated Amortisation
At 1 July 2017	0.6	12.2	2.3	20.4	124.3	159.8
Charge for the year	0.7	8.0	2.1	26.9	16.4	54.1
Foreign exchange adjustments	–	–	–	0.1	0.4	0.5
At 30 June 2018 and 1 July 2018	1.3	20.2	4.4	47.4	141.1	214.4
Charge for the year	2.3	6.8	1.6	55.0	11.1	76.8
Reclassification*	–	–	–	0.2	(0.2)	–
Foreign exchange adjustments	0.1	0.9	0.1	1.7	1.9	4.7
At 30 June 2019	3.7	27.9	6.1	104.3	153.9	295.9
Net book value
At 30 June 2019	3.1	23.5	10.2	289.3	87.8	413.9
At 30 June 2018	5.4	29.4	11.0	319.9	93.9	459.6

* Apex IPR&D acquired October 2016 has been reclassified from Patent rights to Capitalised development costs.

 

The table below provides further detail on the acquired intangibles and their remaining amortisation period.

Significant assets	Description	Carrying value £m	Sub-Total carrying value £m	Remaining amortisation period
Intangible assets arising from the acquisition of Dermapet	Product, marketing and distribution rights	20.4	20.4	6 ½ years
Intangible assets arising from the acquisition of Genetrix	Product, marketing and distribution rights	0.8	0.8	1 ½ years
Intangible assets arising from the acquisition of Eurovet	Technology, product, marketing and distribution rights	25.3	25.3	3 years
Intangible assets arising from the acquisition of PSPC Inc	Product, marketing and distribution rights	3.2	3.2	5 years
Intangible asset acquired from Pharmaderm Animal Health	Marketing and distribution rights	0.5	0.5	3 years
HY-50 intangible asset acquired from Bexinc Limited	Marketing and distribution rights	1.3	1.3	2 ½ years
Intangible assets arising from the acquisition of Genera	Product, brand, technology, marketing and distribution rights	0.8		3 ½ years
		0.4		6 ½ years
		7.4		11 ½ years
			8.6	Genera – total
Intangible assets arising from the acquisition of Putney	Product, brand, technology, pharmacological process, marketing and distribution rights	6.8		7 years
		23.9		7 years
		46.8		9 years
			77.5	Putney – total
Intangible asset arising from the acquisition of Apex	Product and technology	13.4		14 years
		2.1		11 years
		0.2		2 years
			15.7	Apex – total
Intangible asset related to Animal Ethics	Marketing and distribution rights	27.3	27.3	10 years
Intangible asset related to a US dental licensing agreement	Marketing and distribution rights	0.6	0.6	8 years
Intangible asset related to Bioveta	Marketing and distribution rights	2.1	2.1	10 years
Intangible asset related to an injectable solution licensing agreement	Marketing and distribution rights	6.1	6.1	10 years
Intangible assets arising from the acquisition of RxVet	Brand	0.1	0.1	½ year
Intangible assets arising from the acquisition of AST Farma and Le Vet	Product, brand, technology, marketing and distribution rights	72.1 108.3 15.3 1.4 1.8		8 ½ years 7 ½ years 9 years 1 ½ years 3 ½ years
			198.9	AST Farma and Le Vet – total
Intangible asset related to Premune	Product	0.1	0.1	2 years
Intangible assets related to an injectable solution licensing agreement	Marketing and distribution rights	7.9	7.9	15 years
Intangible assets arising from the acquisition of Caledonian	Product, brand, technology, marketing and distribution rights	3.9	3.9	4 ½ years
Intangible assets arising from the acquisition of Venco	Product, brand, technology, marketing and distribution rights	11.9 0.7 0.6 0.4	13.6	9 ½ years 4 ½ years 7 ½ years 1 ½ years Venco –total
			413.9